Find Capmatinib manufacturers, exporters & distributors on PharmaCompass

Capmatinib

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

4 API Suppliers, 4 Listed Suppliers

PRICE INFORMATION

API Reference Price, API Exports, API Imports

DIGITAL CONTENT

8 News

8 News

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

7,676

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 1029712-80-8, Incb28060, Inc280, Inc-280, Nvp-inc280-nx, Incb-28060

Molecular Formula

C₂₃H₁₇FN₆O

Molecular Weight

412.4 g/mol

InChI Key

LIOLIMKSCNQPLV-UHFFFAOYSA-N

FDA UNII

TY34L4F9OZ

Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

Capmatinib is a Kinase Inhibitor. The mechanism of action of capmatinib is as a Mesenchymal Epithelial Transition Inhibitor, and Cytochrome P450 1A2 Inhibitor, and P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor, and Multidrug and Toxin Extrusion Transporter 1 Inhibitor, and Multidrug and Toxin Extrusion Transporter 2 K Inhibitor.

1 2D Structure

Capmatinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

2.1.2 InChI

InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)

2.1.3 InChI Key

LIOLIMKSCNQPLV-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F

2.2 Other Identifiers

2.2.1 UNII

TY34L4F9OZ

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzoic Acid

2. 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)-(1,2,4)triazin-2-yl)benzamide

3. 2-fluoro-n-methyl-4-(7-((quinolin-6-yl)methyl)imidazo(1,2- B)(1,2,4)triazin-2-yl)benzamide Dihydrochloride Monohydrate

4. 2-fluoro-n-methyl-4-(7-(quinolin-6-yl-methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide

5. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide

6. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide Dihydrochloride

7. Capmatinib Dihydrochloride

8. Capmatinib Dihydrochloride Monohydrate

9. Capmatinib Hydrochloride

10. Capmatinib Hydrochloride Anhydrous

11. Capmatinib Metabolite M13

12. Capmatinib Metabolite M18

13. Cmc-583

14. Cmc583

15. Cnj-294

16. Cnj294

17. Inc-280

18. Inc280

19. Incb-28060

20. Incb-28060 Free Base

21. Incb28060

22. Nvp-inc280

23. Nvp-inc280-nx

24. Tabrecta

2.3.2 Depositor-Supplied Synonyms

1. 1029712-80-8

2. Incb28060

3. Inc280

4. Inc-280

5. Nvp-inc280-nx

6. Incb-28060

7. Nvp-inc280

8. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide

9. Tabrecta

10. Capmatinib (incb28060)

11. Capmatinib [usan]

12. Incb-28060 Free Base

13. Inc28060

14. 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

15. Ty34l4f9oz

16. Incb 28060

17. Benzamide, 2-fluoro-n-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-

18. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide

19. Benzamide, 2-fluoro-n-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-;benzamide, 2-fluoro-n-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-

20. Capmatinib [inn]

21. Unii-ty34l4f9oz

22. Benzamide Hcl

23. Benzamide, 2-fluoro-n-methyl-4-(7-(6-quinolinylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)-

24. Capmatinib [mi]

25. Capmatinib (usan/inn)

26. Capmatinib [usan:inn]

27. Capmatinib(incb28060)

28. Incb28060(capmatinib)

29. Nyp-inc280-nx

30. Capmatinib [who-dd]

31. Mls006010965

32. Gtpl7904

33. Schembl1426819

34. Chembl3188267

35. Dtxsid90145595

36. Ex-a446

37. Amy18553

38. Bcp23444

39. Bdbm50146167

40. Mfcd18633285

41. Nsc777878

42. Nsc800067

43. S2788

44. Zinc43195321

45. Akos025396439

46. Bcp9000785

47. Ccg-268791

48. Cs-1541

49. Db11791

50. Nsc-777878

51. Nsc-800067

52. Sb16608

53. Ncgc00346702-01

54. Ncgc00346702-02

55. Ncgc00346702-05

56. Ac-25890

57. As-74142

58. Da-33530

59. Hy-13404

60. Smr004702769

61. Ft-0746310

62. D10696

63. J-509516

64. Q27075685

65. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2- Yl)benzamide

66. 2-fluoro-n-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

67. 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazolo[1,2-b][1,2,4]triazin-2-yl]benzamide

68. 2-fluoro-n-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide

2.4 Create Date

2009-02-09

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₁₇FN₆O
Molecular Weight	412.4 g/mol
XLogP3	2.9
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	4
Exact Mass	412.14478735 g/mol
Monoisotopic Mass	412.14478735 g/mol
Topological Polar Surface Area	85.1 Å²
Heavy Atom Count	31
Formal Charge	0
Complexity	637
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

FDA Label

Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Capmatinib inhibits the overactivity of c-Met, a receptor tyrosine kinase encoded by the _MET_ proto-oncogene. Mutations in _MET_ are involved in the proliferation of many cancers, including non-small cell lung cancer (NSCLC). Capmatinib may cause photosensitivity reactions in patients following ultraviolet (UV) exposure - patients undergoing therapy with capmatinib should be advised to use sunscreen and protective clothing to limit exposure to UV radiation. Instances of interstitial lung disease/pneumonitis, which can be fatal, occurred in patients being treated with capmatinib. Patients presenting with signs or symptoms of lung disease (e.g. cough, dyspnea, fever) should have capmatinib immediately withheld, and capmatinib should be permanently discontinued if no other feasible causes of the lung-related symptoms are identified.

5.2 FDA Pharmacological Classification

5.2.1 Active Moiety

CAPMATINIB

5.2.2 FDA UNII

TY34L4F9OZ

5.2.3 Pharmacological Classes

Cytochrome P450 1A2 Inhibitors [MoA]; Kinase Inhibitor [EPC]; Mesenchymal Epithelial Transition Inhibitors [MoA]; Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]; Multidrug and Toxin Extrusion Transporter 2 K Inhibitors [MoA]; P-Glycoprotein Inhibitors [MoA]; Breast Cancer Resistance Protein Inhibitors [MoA]

5.3 ATC Code

L01EX17

L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EX - Other protein kinase inhibitors

L01EX17 - Capmatinib

5.4 Absorption, Distribution and Excretion

Absorption

The oral bioavailability of capmatinib is estimated to be >70%. Following oral administration, maximum plasma concentrations are achieved within 1 to 2 hours (T_max). Co-administration with a high-fat meal increased capmatinib AUC by 46% with no change in C_max (as compared to fasted conditions), and co-administration with a low-fat meal had no clinically meaningful effects on exposure.

Route of Elimination

Following oral administration of radiolabeled capmatinib, approximately 78% of the radioactivity is recovered in feces, of which ~42% is unchanged parent drug, and 22% is recovered in the urine, of which a negligible amount remains unchanged parent drug.

Volume of Distribution

The apparent volume of distribution at steady-state is 164 L.

Clearance

The mean apparent clearance of capmatinib at steady-state is 24 L/h.

5.5 Metabolism/Metabolites

Capmatinib undergoes metabolism primarily via CYP3A4 and aldehyde oxidase. Specific biotransformation pathways and metabolic products have yet to be elucidated.

5.6 Biological Half-Life

The elimination half-life is 6.5 hours.

5.7 Mechanism of Action

Aberrant activation of c-Met has been documented in many cancers, including non-small cell lung cancer (NSCLC). Mutations that result in the skipping of _MET_ exon 14 lead to the formation of a mutant c-Met with a missing regulatory domain - these mutant proteins have a reduced ability to negatively regulate, leading to a pathological increase in their downstream activity. Capmatinib inhibits the phosphorylation of both wild-type and mutant variants of c-Met triggered by the binding of its endogenous ligand, hepatocyte growth factor - in doing so, it prevents c-Met-mediated phosphorylation of downstream signaling proteins, as well as the proliferation and survival of c-Met-dependent tumor cells.